Altheos, Asahi Kasei Pharma deal

Asahi Kasei granted Altheos exclusive, worldwide rights, excluding Japan and Korea, to develop and commercialize ATS907 for all indications. ATS907, a Rho kinase inhibitor, is in preclinical develop...